Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Divi's Laboratories Limited (DIVISLAB.NS)
INR7,188.50
+250.00 (+3.60%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
Divi Towers 500032
Hyderabad, IN
Hyderabad, IN
CEO
Kiran Satchandra Divi
Website
divislabs.com
IPO
2003-03-12
ISIN INE361B01024
Also trades on
Bombay Stock Exchange · DIVISLAB.BO (INR)
National Stock Exchange of India · DIVISLAB.NS (INR)
Description
Divi's Laboratories Limited, established in 1990 and based in Hyderabad, India, operates globally in the production and distribution of generic active pharmaceutical ingredients (APIs), intermediate chemicals, and nutraceuticals. The company's market footprint encompasses India, the United States, Asia, Europe, and other international regions. In addition to its core product lines, Divi's offers bespoke synthesis services for APIs and intermediates. It also provides a diverse range of carotenoids and markets various vitamins, catering to the nutritional, pharmaceutical, food and beverage, and animal feed industries. The firm was formerly known as Divi's Research Center before rebranding to Divi's Laboratories Limited in 1994.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR7,188.50
+250.00 (+3.60%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
345.3K
Beta
0.22
Float Shares
117.74M
Free Float %
44.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.61% | +2.21% | +8.46% | +10.30% | +8.51% | +7.94% | +2.42% | +103.95% | +68.41% | +569.74% | +78,220.09% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
7,188.50
DCF (Unlevered)
4,353.20
-39.4%
DCF (Levered)
3,658.34
-49.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
48% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 11 | 0 |
| Hold | 6 | 0 |
| Sell | 2 | -2 |
| Strong Sell | 8 | 0 |
Quality scores
Altman Z-Score
35.13
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✓ MOAT relativo
★ Strong MOAT
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+13.2% ★ Q1'26: +11.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+17.2% ★ Q1'26: +13.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+21.2% ★ Q1'26: +3.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+28.2% ★ Q1'26: +28.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+16.9% ★ Q1'26: +19.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%0.0% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× ★ Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2010 actual |
Mar 2011 actual |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 30 Rev. Ana. 25 EPS Ana. |
Mar 2027 29 Rev. Ana. 26 EPS Ana. |
Mar 2028 28 Rev. Ana. 25 EPS Ana. |
Mar 2029 19 Rev. Ana. 11 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
9.42B
est: 9.27B (+1.6%)
|
13.17B
est: 11.69B (+12.6%)
|
18.64B
est: 16.49B (+13.1%)
|
21.45B
est: 22.89B (-6.3%)
|
25.32B
est: 25.78B (-1.8%)
|
31.15B
est: 31.05B (+0.3%)
|
37.69B
est: 36.05B (+4.5%)
|
40.53B
est: 41.90B (-3.3%)
|
38.07B
est: 38.98B (-2.3%)
|
48.04B
est: 49.10B (-2.2%)
|
52.91B
est: 54.37B (-2.7%)
|
68.58B
est: 68.82B (-0.3%)
|
87.99B
est: 87.05B (+1.1%)
|
76.65B
est: 76.60B (+0.1%)
|
77.96B
est: 81.85B (-4.8%)
|
93.25B
est: 93.12B (+0.1%)
|
106.20B
103.82B – 111.87B
+14.1% YoY
|
122.89B
116.02B – 132.72B
+15.7% YoY
|
144.79B
128.75B – 166.75B
+17.8% YoY
|
171.39B
156.72B – 191.74B
+18.4% YoY
|
| EBITDA |
3.46B
est: 3.64B (-4.9%)
|
5.27B
est: 5.62B (-6.2%)
|
7.45B
est: 7.73B (-3.5%)
|
8.59B
est: 10.76B (-20.1%)
|
10.84B
est: 10.14B (+6.9%)
|
12.09B
est: 14.06B (-14.1%)
|
15.13B
est: 14.63B (+3.5%)
|
15.20B
est: 18.55B (-18.1%)
|
13.74B
est: 14.62B (-6.0%)
|
20.26B
est: 18.91B (+7.1%)
|
20.11B
est: 23.79B (-15.4%)
|
29.22B
est: 25.41B (+15.0%)
|
39.95B
est: 29.75B (+34.3%)
|
27.12B
est: 35.50B (-23.6%)
|
25.44B
est: 31.37B (-18.9%)
|
33.20B
est: 36.08B (-8.0%)
|
40.70B
39.79B – 42.88B
+12.8% YoY
|
47.10B
44.47B – 50.86B
+15.7% YoY
|
55.49B
49.35B – 63.91B
+17.8% YoY
|
65.69B
60.06B – 73.49B
+18.4% YoY
|
| EBIT |
2.95B
est: 3.71B (-20.5%)
|
4.74B
est: 4.49B (+5.5%)
|
6.83B
est: 6.17B (+10.8%)
|
7.82B
est: 8.73B (-10.4%)
|
9.92B
est: 8.32B (+19.2%)
|
10.73B
est: 11.29B (-5.0%)
|
13.95B
est: 12.12B (+15.1%)
|
13.97B
est: 15.08B (-7.4%)
|
12.32B
est: 12.88B (-4.3%)
|
18.57B
est: 14.34B (+29.5%)
|
18.25B
est: 18.67B (-2.2%)
|
26.66B
est: 20.02B (+33.2%)
|
36.84B
est: 23.44B (+57.1%)
|
23.69B
est: 27.97B (-15.3%)
|
21.66B
est: 27.95B (-22.5%)
|
29.18B
est: 32.15B (-9.2%)
|
36.26B
35.45B – 38.20B
+12.8% YoY
|
41.96B
39.62B – 45.32B
+15.7% YoY
|
49.44B
43.96B – 56.94B
+17.8% YoY
|
58.52B
53.51B – 65.47B
+18.4% YoY
|
| Net Income |
3.40B
est: 3.29B (+3.5%)
|
4.29B
est: 4.29B (+0.1%)
|
5.33B
est: 6.04B (-11.7%)
|
6.02B
est: 7.40B (-18.6%)
|
7.73B
est: 6.78B (+14.1%)
|
8.52B
est: 9.44B (-9.8%)
|
11.26B
est: 9.96B (+13.0%)
|
10.60B
est: 13.03B (-18.6%)
|
8.77B
est: 10.02B (-12.5%)
|
13.53B
est: 11.17B (+21.1%)
|
13.77B
est: 14.81B (-7.0%)
|
19.84B
est: 16.80B (+18.1%)
|
29.60B
est: 19.68B (+50.5%)
|
18.24B
est: 14.77B (+23.5%)
|
16.00B
est: 16.74B (-4.4%)
|
21.91B
est: 23.06B (-5.0%)
|
25.58B
24.50B – 28.16B
+10.9% YoY
|
30.91B
27.28B – 34.54B
+20.8% YoY
|
37.79B
32.99B – 45.20B
+22.3% YoY
|
46.34B
41.18B – 53.50B
+22.6% YoY
|
| SGA |
745.56M
est: 789.95M (-5.6%)
|
778.50M
est: 1.27B (-38.6%)
|
703.16M
est: 1.65B (-57.5%)
|
2.84B
est: 2.11B (+34.5%)
|
3.17B
est: 2.24B (+41.4%)
|
2.93B
est: 3.43B (-14.6%)
|
3.67B
est: 4.09B (-10.2%)
|
5.09B
est: 5.10B (-0.1%)
|
4.65B
est: 5.29B (-12.1%)
|
5.53B
est: 6.82B (-19.0%)
|
6.32B
est: 9.65B (-34.5%)
|
8.37B
est: 12.96B (-35.4%)
|
9.57B
est: 15.18B (-36.9%)
|
9.87B
est: 18.10B (-45.5%)
|
11.06B
est: 10.42B (+6.2%)
|
12.58B
est: 11.98B (+5.0%)
|
13.52B
13.21B – 14.24B
+12.8% YoY
|
15.64B
14.76B – 16.89B
+15.7% YoY
|
18.43B
16.39B – 21.22B
+17.8% YoY
|
21.81B
19.94B – 24.40B
+18.4% YoY
|
| EPS |
13.06
est: 11.06 (+18.1%)
|
16.21
est: 14.16 (+14.5%)
|
20.10
est: 18.65 (+7.7%)
|
22.68
est: 24.86 (-8.8%)
|
29.13
est: 31.11 (-6.4%)
|
32.08
est: 32.07 (+0.0%)
|
42.41
est: 40.26 (+5.4%)
|
39.95
est: 44.54 (-10.3%)
|
33.04
est: 32.63 (+1.2%)
|
50.96
est: 52.08 (-2.1%)
|
51.85
est: 51.75 (+0.2%)
|
74.75
est: 75.23 (-0.6%)
|
111.52
est: 104.25 (+7.0%)
|
68.69
est: 71.50 (-3.9%)
|
60.27
est: 63.06 (-4.4%)
|
82.53
est: 81.08 (+1.8%)
|
97.66
92.31 – 106.09
+20.4% YoY
|
114.41
102.77 – 130.13
+17.2% YoY
|
139.50
124.31 – 170.28
+21.9% YoY
|
174.59
155.16 – 201.54
+25.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
10.19B
OE per share TTM
38.39
Owner's Yield
0.56%
Maintenance CapEx ratio
28.85%
Maint CapEx / Avg PPE
64.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
3.06M
Shares Outstanding
265.47M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Murali Krishna Prasad Divi | MD & Executive Director | 882M | — |
| Venkata Ramana Nimmagadda | Executive Director | 452M | male |
| Kiran Satchandra Divi | Chief Executive Officer & Whole-Time Director | 308M | — |
| Nilima Prasad Divi | Whole-time Director, Chief Control Officer & Director of Commercial | 307M | female |
| Devendra Rao Sureddy | Whole-Time Director (Manufacturing) | 31M | — |
| Y. T. S. Prasad | Global Quality Head | — | male |
| Manoranjan Jasti | Chief Information Officer | — | male |
| Satish Choudhury | Company Secretary & Compliance Officer | — | male |
| Satya Prakash Divi | Vice President of Sales, Marketing & Logistics | — | male |
| Venkatesa Perumallu Pasumarthy | Chief Financial Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DIVISLAB.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
